TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA.
Curr Cardiol Rep. 2024 Sep;26(9):911-917. doi: 10.1007/s11886-024-02100-y. Epub 2024 Jul 23.
This review provides an overview of the factor XI (FXI) inhibitor hypothesis for the development of novel anticoagulants which may be safer to those currently used in clinical practice and describes preliminary clinical data from phase 2 dose-ranging studies of patients with atrial fibrillation.
Recent data from phase 2 dose ranging studies demonstrate substantial reductions in bleeding with FXI pathway inhibition compared with currently approved anticoagulants. However, larger studies are necessary to demonstrate efficacy of FXI inhibition for stroke prevention in atrial fibrillation. FXI pathway inhibition holds great promise for revolutionizing the landscape of anticoagulation for atrial fibrillation, primarily by reducing bleeding risk; however, further data are necessary to demonstrate efficacy.
本文综述了因子 XI（FXI）抑制剂假说在新型抗凝剂开发中的应用，这些新型抗凝剂可能比目前临床实践中使用的抗凝剂更安全，并描述了心房颤动患者 2 期剂量范围研究的初步临床数据。
来自 2 期剂量范围研究的最新数据表明，与目前批准的抗凝剂相比，FXI 通路抑制可显著减少出血。然而，需要更大规模的研究来证明 FXI 抑制在预防心房颤动中的疗效。FXI 通路抑制为心房颤动的抗凝治疗带来了革命性的前景，主要通过降低出血风险；然而，还需要进一步的数据来证明其疗效。
